C12E8 (Synonyms: Octaethylene Glycol Monododecyl Ether) |
カタログ番号GC43020
One-Click Copy Product Info
|
C12E8は非イオンの界面活性剤であり、正式名称は界面活性剤ポリオキシエチレングリコールであり、ポリオキシエチレンエーテル界面活性剤に属している。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 3055-98-9
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
C12E8は非イオンの界面活性剤であり、正式名称は界面活性剤ポリオキシエチレングリコールであり、ポリオキシエチレンエーテル界面活性剤に属している[1]。C12E8は、リン脂質小胞膜の曲率と形態変化を濃度依存的に調節し、低濃度で天然形態の変化を促進し、異常な変形を誘発し、高濃度では最終的に小胞崩壊に導く[2-3]。
DC3F細胞で、C12E8 (0.05mg/mL；45分間)は、平面脂質二重層で、不可逆的電気穿孔法に必要な電圧を下げる[4]。赤血球で、C12E8 (44μM; 60分間)で処理された赤血球の切片で、圧縮された中央領域と球状の周辺部を持つ、大きな平らな陥入部/小胞が発見された[5]。
References:
[1]. Ruiz CC, Molina-Bolívar JA. Characterization of mixed non-ionic surfactants n-octyl-β-d-thioglucoside and octaethylene–glycol monododecyl ether: Micellization and microstructure. Journal of colloid and interface science. 2011 Sep 1; 361(1): 178-185.
[2]. Mavcic B, Babnik B, Iglic A, et al. Shape transformation of giant phospholipid vesicles at high concentrations of C12E8. Bioelectrochemistry. 2004 Jun 1; 63(1-2): 183-187.
[3]. Guo Y. Surface interactions between poly (ethylene glycol) and phospholipid bilayers: Effects on aggregation and fusion. State University of New York at Buffalo; 1993.
[4]. Kanduser M, Fosnaric M, Sentjurc M, et al. Effect of surfactant polyoxyethylene glycol (C12E8) on electroporation of cell line DC3F. Colloids and Surfaces A: Physicochemical and Engineering Aspects. 2003 Mar 12; 214(1-3): 205-217.
[5]. Bobrowska-Hägerstrand M, Kralj-Iglič V, Iglič A, et al. Torocyte membrane endovesicles induced by octaethyleneglycol dodecylether in human erythrocytes. Biophysical journal. 1999 Dec 1; 77(6): 3356-3362.
| 細胞実験[1]: | |
細胞株 | DC3F細胞 |
準備方法 | 懸濁液の中の細胞を37℃で45分間培養した；処理された細胞に0.05mg/mL C12E8を添加し、C12E8が溶解された培地を未処理の細胞に添加した。膜流動性を電子常磁性共鳴法(EPR)で測定し、スピンプローブ 5-ドキシルパルミチン酸メチルエステル (MeDALS)を使った。これは親油性であるため、主に膜脂質二重層に組み込まれる。エタノール溶液の中の60mlの0.1mM MeFASLをガラス管に置き、エタノールをロータリー式蒸発器で蒸発させた。20 × 106細胞を含有した1mLの細胞懸濁液を、ガラス管の壁に形成されたMeFASLフィルムに添加し、振盪しながら15分間培養した。その後、細胞懸濁液を遠心分離し、ペレットをEPR測定のために、ガラス毛細管に置いた。4℃で、EPRスペクトルから、秩序パラメーターを反映する最大の超微細分裂定数2AIIを測定した。 |
反応条件 | 0.05mg/mL；45分間 |
アプリケーション | C12E8は、平面脂質二重層で、不可逆的電気穿孔法に必要な電圧を下げる。 |
References: | |
| Cas No. | 3055-98-9 | SDF | |
| 同義語 | Octaethylene Glycol Monododecyl Ether | ||
| Canonical SMILES | CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCO | ||
| Formula | C28H58O9 | M.Wt | 538.8 |
| 溶解度 | DMF: 30 mg/ml,DMSO: 15 mg/ml,Ethanol: 30 mg/ml,PBS (pH 7.2): 1 mg/ml | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.856 mL | 9.2799 mL | 18.5598 mL |
| 5 mM | 371.2 μL | 1.856 mL | 3.712 mL |
| 10 mM | 185.6 μL | 928 μL | 1.856 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: An oil
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 26 reference(s) in Google Scholar.)